Actinic keratoses: past, present and future.
Actinic keratoses (AKs) are cutaneous neoplasms composed of proliferations of cytologically aberrant, epidermal keratinocytes caused by prolonged exposure to ultraviolet radiation. Combining the evidence that AKs are the second most common reason for visits to the dermatologist and it is generally believed that they should be treated, it is no surprise that the direct cost of the management of actinic keratoses in the United States (U.S.) is exceedingly high. There are currently numerous treatment modalities with more on the way as there is a demand for formulating newer, cheaper, less painful and less invasive means. The future of AK treatment involves both the continued investigation of current novel therapies, as well as the development of new treatment modalities.
Fenske
Neil Alan
NA
University of South Florida College of Medicine,Tampa, FL, USA.
Spencer
James
J
Adam
Friedman
F
D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000634:Aminoquinolines / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy; D003452:Cryosurgery; D004008:Diclofenac / Q000627:therapeutic use; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D000077271:Imiquimod; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D055623:Keratosis, Actinic / Q000473:pathology / Q000628:therapy*; D010778:Photochemotherapy; D011230:Precancerous Conditions / Q000473:pathology / Q000628:therapy; D012878:Skin Neoplasms / Q000473:pathology / Q000628:therapy
D000276:Adjuvants, Immunologic; D000634:Aminoquinolines; D000894:Anti-Inflammatory Agents, Non-Steroidal; D007166:Immunosuppressive Agents; D004008:Diclofenac; D000077271:Imiquimod; D005472:Fluorouracil